Pharming Group

Pharming Group R&D per Employee

The R&D Spending per Employee of Pharming Group (PHAR) as of Oct 15, 2026 is 55,759.44 USD. In the previous year, R&D Spending per Employee was 47,832.16 USD — a change of 16.57% (higher).

R&D per Employee

55,759.44USD

YoY

16.57%

Last updated:

R&D Spending per Employee of Pharming Group is 2025 55,759.44 USD. R&D Spending per Employee of Pharming Group was 2024 47,832.16 USD. It decreases by 16.57% higher compared to the previous year.

The Pharming Group R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
18,354.56 USD
Jan 1, 2019
17,658.89 USD
Jan 1, 2020
21,399.44 USD
Jan 1, 2021
44,321.16 USD
Jan 1, 2022
29,183.89 USD
Jan 1, 2023
38,285.56 USD
Jan 1, 2024
47,832.16 USD
Jan 1, 2025
55,759.44 USD
The Pharming Group R&D per Employee history
YEARR&D per EmployeeYoY
55,759.44USD+16.57%
47,832.16USD+24.94%
38,285.56USD+31.19%
29,183.89USD-34.15%
44,321.16USD+107.11%
21,399.44USD+21.18%
17,658.89USD-3.79%
18,354.56USD+47.60%
12,434.92USD+38.31%
8,990.88USD+4.39%
8,612.79USD+9.31%
7,879.09USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group NV is a biopharmaceutical company based in Leiden, Netherlands, listed on the stock market with the ticker PHAR and ISIN US71716E1055. The company operates in the Health Care sector, specifically within the Health Care industry, and employs approximately 1,800 people. Pharming Group NV went public through an IPO on December 23, 2020. Its website is https://www.pharming.com. The company focuses on developing and commercializing protein replacement therapies and precision medicines for rare diseases. While the provided source mentions specific products like RUCONEST and Joenja, these details are treated as untrusted facts and are not included in this profile. Pharming Group NV is incorporated in the United States, though it is headquartered in Leiden, Netherlands. The company has a development collaboration and license agreement with Novartis, as noted in the source. Pharming Group NV's activities span the United States, Europe, and internationally. The company's primary focus is on rare diseases, and it is engaged in the research, development, and commercialization of innovative therapeutic solutions. The company's corporate structure and operations are centered around its headquarters in Leiden, with a global reach in the healthcare market. The exact founding year is not provided in the user message, so it is omitted from this profile. The company's product pipeline and specific therapeutic areas are not detailed beyond the general focus on rare diseases. Pharming Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharming Group stock

R&D Spending per Employee of Pharming Group is 55,759.44 USD in 2025.

R&D Spending per Employee of Pharming Group changed from 47,832.16 USD to 55,759.44 USD, representing a 16.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Pharming Group since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Pharming Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Pharming Group

All Key Metrics — Pharming Group